Celldex Therapeutics, Inc. filed a Form 8-K on September 22, 2026, announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU).
Key Highlights
- Trial Results Announced: Celldex Therapeutics disclosed results from two Phase 3 trials, EMBARQ-CSU1 and EMBARQ-CSU2, evaluating Barzolvolimab in chronic spontaneous urticaria.
- Drug Candidate: The trials assessed Barzolvolimab, the company's investigational therapy being studied in the CSU indication.
- Two Concurrent Studies: Both EMBARQ-CSU1 and EMBARQ-CSU2 are identified as Phase 3 trials, according to the filing.
- Press Release Attached: The company attached the full press release as Exhibit 99.1, dated September 22, 2026, which is incorporated by reference into the filing.
- Signed by CFO: The filing was signed by Sam Martin, Senior Vice President and Chief Financial Officer, on September 22, 2026.
Celldex Discloses Phase 3 Barzolvolimab Data in Chronic Spontaneous Urticaria
Celldex Therapeutics, Inc. (NASDAQ:CLDX), incorporated in Delaware and headquartered at Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey, filed a current report on September 22, 2026, under Item 8.01 (Other Events) of Form 8-K. According to the filing, the company issued a press release on that date announcing results from its Phase 3 clinical program in chronic spontaneous urticaria.
The filing identifies two separate Phase 3 trials, designated EMBARQ-CSU1 and EMBARQ-CSU2, both evaluating the company's drug candidate Barzolvolimab in CSU. The filing does not itself summarize the trial outcome data; instead, it states that the full results are contained in the attached press release, Exhibit 99.1, which is incorporated by reference into the 8-K. The filing does not reproduce specific efficacy, safety, or statistical figures within the body of the current report.
The report was signed by Sam Martin, identified as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. The company indicated it is not an emerging growth company. The common stock, par value $0.001 per share, trades under the symbol CLDX on the Nasdaq Capital Market.
What Was Disclosed
Celldex Therapeutics filed an 8-K on September 22, 2026, to report that Phase 3 trial results for Barzolvolimab in CSU were announced via press release. The detailed results are contained in Exhibit 99.1 attached to the filing.



Please wait processing your request...